To Debiopharm Group\'s Debio 025 (alisporivir) for the treatment of hepatitis
Novartis has won exclusive, worldwide rights to Debiopharm Group\'s Debio 025 (alisporivir) for the treatment of hepatitis.
Debiopharm has granted Novartis worldwide commercialisation rights, except in Japan.
Under the terms of the agreement, Novartis will pay Swiss biopharmaceutical Debiopharm an upfront payment, development and sales milestones, as well as royalties.
Debio 025 is a selective cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C.